Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Hare, Jennifer I ^a   Neijzen, Robert W ^b   Anantha, Malathi ^c   Dos Santos, Nancy ^c   Harasym, Natashia ^d   Webb, Murray S ^d   Allen, Theresa M ^a,d   Bally, Marcel B ^c,d,e   Waterhouse, Dawn N ^c,e  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UTRECHT UNIVERSITY   (Netherlands)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

^d Centre for Drug Research and Development   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IRINOPHORE C; IRINOTECAN; UNCLASSIFIED DRUG; CAMPTOTHECIN; DRUG COMBINATION; LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERM EXPOSURE; MONOTHERAPY; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; COLORECTAL NEOPLASMS; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; FEMALE; HT 29 CELL LINE; MALE; PATHOLOGY; TOXICITY; TUMOR CELL LINE; TUMOR VOLUME;

MUS;

ANIMALS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; HT29 CELLS; HUMANS; LIPOSOMES; MALE; MICE; TUMOR BURDEN;

EID: 84876584767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062349     Document Type: Article

References (73)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. American Cancer Society (2008) Global Cancer Facts & Figures 2nd Edition. Atlanta: American Cancer Society.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
4. American Cancer Society (2013) Cancer Facts & Figures 2013. Atlanta: American Cancer Society.
5. American Cancer Society (2011) Colorectal Cancer Facts & Figures 2011-2013. Atlanta: American Cancer Society.
6. Senter PD, Beam KS, Mixan B, Wahl AF, (2001) Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem 12: 1074-1080.
7. Xu G, Zhang W, Ma MK, McLeod HL, (2002) Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res 8: 2605-2611.
8. Humerickhouse R, Lohrbach K, Li L, Bosron WF, Dolan ME, (2000) Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 60: 1189-1192.
9. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K, (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191.
10. Lavelle F, Bissery MC, Andre S, Roquet F, Riou JF, (1996) Preclinical evaluation of CPT-11 and its active metabolite SN-38. Semin Oncol 23: 11-20.
11. Khanna R, Morton CL, Danks MK, Potter PM, (2000) Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 60: 4725-4728.
12. Guichard S, Terret C, Hennebelle I, Lochon I, Chevreau P, et al. (1999) CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 80: 364-370.
13. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA, 3rd, Nelson J, et al (1996) Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135.
14. Rothenberg ML, Cox JV, DeVore RF, Hainsworth JD, Pazdur R, et al. (1999) A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer 85: 786-795.
15. Saliba F, Hagipantelli R, Misset JL, Bastian G, Vassal G, et al. (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J Clin Oncol 16: 2745-2751.
16. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, et al. (2001) Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7: 2182-2194.
17. Fassberg J, Stella VJ, (1992) A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 81: 676-684.
18. Rivory LP, Chatelut E, Canal P, Mathieu-Boue A, Robert J, (1994) Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res 54: 6330-6333.
19. Burke TG, Mi Z, (1994) The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37: 40-46.
20. Drummond DC, Noble CO, Guo Z, Hong K, Park JW, et al. (2006) Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res 66: 3271-3277.
21. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, et al. (2008) Irinophore C: a liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res 14: 1208-1217.
22. Nakajima TE, Yasunaga M, Kano Y, Koizumi F, Kato K, et al. (2008) Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. Int J Cancer 122: 2148-2153.
23. Hattori Y, Shi L, Ding W, Koga K, Kawano K, et al. (2009) Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release 136: 30-37.
24. Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, et al. (2010) Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine 6: 478-485.
25. Peng CL, Lai PS, Lin FH, Yueh-Hsiu Wu S, Shieh MJ, (2009) Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials 30: 3614-3625.
26. Ramsay E, Alnajim J, Anantha M, Zastre J, Yan H, et al. (2008) A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. Eur J Pharm Biopharm 68: 607-617.
27. Ramsay E, Alnajim J, Anantha M, Taggar A, Thomas A, et al. (2006) Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res 23: 2799-2808.
28. Patankar N, Anantha M, Ramsay E, Waterhouse D, Bally M, (2011) The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C. Pharm Res. 28: 848-857.
29. Verreault M, Strutt D, Masin D, Anantha M, Yung A, et al. (2011) Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C), doxorubicin (Caelyx(R)) or vincristine. BMC Cancer 11: 124-141.
30. Messerer CL, Ramsay EC, Waterhouse D, Ng R, Simms EM, et al. (2004) Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer. Clin Cancer Res 10: 6638-6649.
31. Baker JH, Lam J, Kyle AH, Sy J, Oliver T, et al. (2008) Irinophore C, a novel nanoformulation of irinotecan, alters tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin Cancer Res 14: 7260-7271.
32. Fields RD, Lancaster MV, (1993) Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am Biotechnol Lab 11: 48-50.
33. Page B, Page M, Noel C, (1993) A new fluorometric assay for cytotoxicity measurements in vitro. Int J Oncol 3: 473-476.
34. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
35. Chou TC, (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58: 621-681.
36. Hope MJ, Bally MB, Mayer LD, Janoff AS, Cullis PR, (1986) Generation of multilamellar and unilamellar phospholipid vesicles. Chem Phys Lipids 40: 89-96.
37. Hope MJ, Bally MB, Webb G, Cullis PR, (1985) Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim Biophys Acta 812: 55-65.
38. Pool GL, French ME, Edwards RA, Huang L, Lumb RH, (1982) Use of radiolabelled hexadecyl cholesterol ether as a liposome marker. Lipids 17: 445-452.
39. Guichard S, Cussac D, Hennebelle I, Bugat R, Canal P, (1997) Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int J Cancer 73: 729-734.
40. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, et al. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914.
41. Saltz LB, Douillard JY, Pirotta N, Alakl M, Gruia G, et al. (2001) Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6: 81-91.
42. Harasym TO, Tardi PG, Harasym NL, Harvie P, Johnstone SA, et al. (2007) Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios. Oncol Res 16: 361-374.
43. Thomas AM, Kapanen AI, Hare JI, Ramsay E, Edwards K, et al. (2011) Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J Control Release 150: 212-219.
44. Hwang JJ, (2004) Irinotecan and 5-FU/leucovorin in metastatic colorectal cancer: balancing efficacy, toxicity, and logistics. Oncology (Williston Park) 18: 26-34.
45. Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301-308.
46. Liu C, Willingham M, Liu J, Gmeiner WH, (2002) Efficacy and safety of FdUMP[10] in treatment of HT-29 human colon cancer xenografts. Int J Oncol 21: 303-308.
47. Sugarbaker PH, Gianola FJ, Speyer JL, Wesley R, Barofsky I, et al. (1985) Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 12: 101-111.
48. Fraile RJ, Baker LH, Buroker TR, Horwitz J, Vaitkevicius VK, (1980) Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 40: 2223-2228.
49. Fajardo AD, Tan B, Reddy R, Fleshman J, (2012) Delayed repeated intraperitoneal chemotherapy after cytoreductive surgery for colorectal and appendiceal carcinomatosis. Dis Colon Rectum 55: 1044-1052.
50. Tan BR, Mutch M, Picus J, Dietz D, Birnbaum E, et al. (2005) Bi-weekly intraperitoneal (IP) 5FU chemotherapy with systemic oxaliplatin-based therapy in patients with pseudomyxoma peritonei (PP) and peritoneal carcinomatosis (PC) from colorectal cancer (CRC). American Society of Clinical Oncology Meetings: Abstract #272.
51. Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, et al. (2000) Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann Surg 231: 449-456.
52. Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, et al. (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15: 3223-3229.
53. Miyazaki K, Shibahara T, Sato D, Uchida K, Suzuki H, et al. (2006) Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol 41: 140-150.
54. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB, (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203-2206.
55. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, et al. (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7: 1149-1153.
56. Mullany S, Svingen PA, Kaufmann SH, Erlichman C, (1998) Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. Cancer Chemother Pharmacol 42: 391-399.
57. Guichard S, Hennebelle I, Bugat R, Canal P, (1998) Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 55: 667-676.
58. Saltz LB, Kanowitz J, Kemeny NE, Schaaf L, Spriggs D, et al. (1996) Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 14: 2959-2967.
59. Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, et al. (2001) Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 19: 3456-3462.
60. Wiseman LR, Markham A, (1996) Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer. Drugs 52: 606-623.
61. Houghton JA, Houghton PJ, Wooten RS, (1979) Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res 39: 2406-2413.
62. Machover D, (1997) A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 80: 1179-1187.
63. Azrak RG, Cao S, Slocum HK, Toth K, Durrani FA, et al. (2004) Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res 10: 1121-1129.
64. Mans DR, Grivicich I, Peters GJ, Schwartsmann G, (1999) Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur J Cancer 35: 1851-1861.
65. Jain RK, (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7: 987-989.
66. Barone C, Landriscina M, Quirino M, Basso M, Pozzo C, et al. (2007) Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. Br J Cancer 96: 21-28.
67. Mayer LD, Harasym TO, Tardi PG, Harasym NL, Shew CR, et al. (2006) Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther 5: 1854-1863.
68. Mayer LD, Janoff AS, (2007) Optimizing combination chemotherapy by controlling drug ratios. Mol Interv 7: 216-223.
69. Pavillard V, Kherfellah D, Richard S, Robert J, Montaudon D, (2001) Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. Br J Cancer 85: 1077-1083.
70. Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, et al. (2009) Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther 8: 2266-2275.
71. Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, et al. (2009) In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res 33: 129-139.
72. Arbuck SG, (1989) Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer 63: 1036-1044.
73. Advanced Colorectal Cancer Meta-Analysis Project (1992) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project. J Clin Oncol 10: 896-903.